文献速递造血干细胞移植与细胞治疗白血病

首次缓解期急性淋巴细胞白血病患者接受体内T细胞去除减强度预处理异基因造血干细胞移植:UKALL14试验前瞻性单臂评估结果

In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.
PubMed 文献 · Lancet Haematol · 2022-01-01

UKALL14试验的前瞻性单臂移植子研究纳入249例首次完全缓解的急性淋巴细胞白血病患者(236例≥41岁),给予氟达拉滨、美法仑和阿仑单抗减强度预处理后行异基因造血干细胞移植;中位随访49个月,4年无事件生存率46.8%、总生存率54.8%,复发累积发生率33.6%、移植相关死亡率19.6%,诱导后MRD可检测者无事件生存更差(HR 2.40)。

要点

  • ≥41岁首次缓解急性淋巴细胞白血病患者接受FMA减强度预处理移植,4年无事件生存率46.8%、总生存率54.8%。
  • 4年复发累积发生率33.6%,移植相关死亡率19.6%;48例移植相关死亡中27例(56%)死因为感染。
  • 诱导后MRD可检测者无事件生存更差(HR 2.40,95%CI 1.46-3.93)。

核心结论

  • FMA减强度预处理异基因造血干细胞移植用于老年首次完全缓解急性淋巴细胞白血病患者可获得良好疾病控制、中度移植物抗宿主病,无事件生存和总生存优于该高危人群的预期。
  • 作者认为减少感染相关移植相关死亡率的策略将进一步改善结局。

研究设计与样本

  • UKALL14试验内的单臂前瞻性研究,在英国46个中心招募移植子研究患者。
  • 入组患者为B细胞或T细胞急性淋巴细胞白血病,BCR-ABL1阴性者25-65岁、BCR-ABL1阳性者18-65岁,并有合适的匹配同胞供者或8/8等位基因匹配无关供者(HLA-A、HLA-B、HLA-C、HLA-DR)。
  • 2014年6月20日方案修订允许高危细胞遗传学或第二次诱导疗程后MRD阳性的患者使用7/8匹配无关供者。
  • 预处理为氟达拉滨、美法仑和阿仑单抗(FMA):静脉氟达拉滨30 mg/m2第-6至-2天,美法仑140 mg/m2第-2天,阿仑单抗30 mg第-1天(同胞供者)及第-2和-1天(无关供者)。
  • 主要终点为无事件生存,次要及移植特异性终点包括总生存、复发率、移植相关死亡率和急慢性移植物抗宿主病。

主要发现

  • 2011年2月22日至2018年7月26日,249例(236例≥41岁、13例<41岁)被认为不适合清髓性移植的患者接受了FMA减强度预处理移植;138例(55%)男性、111例(45%)女性。
  • 88例(35%)接受同胞供者移植,160例(64%)接受无关供者移植;211例(85%)为B前体急性淋巴细胞白血病。
  • 43例(22%)存在高危细胞遗传学,另63例(25%)为BCR-ABL1阳性。
  • 中位随访49个月(IQR 36-70),4年无事件生存率46.8%(95%CI 40.1-53.2),4年总生存率54.8%(95%CI 48.0-61.2)。
  • 4年复发累积发生率33.6%(95%CI 27.9-40.2),4年移植相关死亡率19.6%(95%CI 15.1-25.3)。

关键数值与推荐

  • 48例移植相关死亡中27例(56%)以感染为指定死因;7例(15%)真菌感染、13例(27%)细菌感染(其中6例革兰阴性)、11例(23%)病毒感染(3例巨细胞病毒、2例EB病毒)。
  • 2-4级急性移植物抗宿主病发生于247例中的29例(12%),3-4级发生于12例(5%)。
  • 慢性移植物抗宿主病发生率为228例中的84例(37%),其中50例(22%)为广泛型。
  • 162例中49例(30%)诱导结束时MRD可检测,其无事件生存更差(HR 2.40,95%CI 1.46-3.93),至复发时间也更差(HR 2.41,95%CI 1.29-4.48)。

临床怎么用

  • 作者认为,FMA减强度预处理异基因造血干细胞移植可为老年首次完全缓解急性淋巴细胞白血病患者带来良好疾病控制和优于预期的生存。
  • 作者认为减少感染相关移植相关死亡率的策略将进一步改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The outcome of chemotherapy in patients older than 40 years with acute lymphoblastic leukaemia is poor and myeloablative allogeneic haematopoietic stem-cell transplantation (HSCT) has a high transplant-related mortality (TRM) in this age cohort. The aim of this study was to assess the activity and safety of reduced-intensity conditioned allogeneic HSCT in this patient population. METHODS: This was a single-arm, prospective study within the UKALL14 trial done in 46 centres in the UK, which recruited patients to the transplantation substudy. Participants in UKALL14 had B-cell or T-cell acute lymphoblastic leukaemia, were aged 25-65 years (BCR-ABL1-negative) or 18-65 years (BCR-ABL1-positive), and for this subcohort had a fit, matched sibling donor or an 8 out of 8 allelic matched unrelated donor (HLA-A, HLA-B, HLA-C, and HLA-DR). On June 20, 2014, the protocol was amended to allow 7 out of 8 matched unrelated donors if the patient had high risk cytogenetics or was minimal residual disease (MRD)-positive after the second induction course. Patients were given fludarabine, melphalan, and alemtuzumab (FMA; intravenous fludarabine 30 mg/m2 on days -6 to -2, melphalan 140 mg/m2 on day -2, and alemtuzumab 30 mg on day -1 [sibling donor] and days -2 and -1 [unrelated donor]) before allogeneic HSCT (aged ≥41 years patient pathway). Donor lymphocyte infusions were given from 6 months for mixed chimerism or MRD. The primary endpoint was event-free survival and secondary and transplantation-specific endpoints included overall survival, relapse incidence, TRM, and acute and chronic graft-versus-host disease (GVHD). This study is registered with ClinicalTrials.gov, NCT01085617. FINDINGS: From Feb 22, 2011, to July 26, 2018, 249 patients (236 aged ≥41 years and 13 younger than 41 years) considered unfit for a myeloablative allograft received an FMA reduced-intensity conditioned HSCT. 138 (55%) patients were male and 111 (45%) were female. 88 (35%) participants received transplantations from a sibling donor and 160 (64%) received transplantations from unrelated donors. 211 (85%) participants had B-precursor acute lymphoblastic leukaemia. High-risk cytogenetics were present in 43 (22%) and another 63 (25%) participants were BCR-ABL1-positive. At median follow-up of 49 months (IQR 36-70), 4-year event-free survival was 46·8% (95% CI 40·1-53·2) and 4-year overall survival was 54·8% (48·0-61·2). 4-year cumulative incidence of relapse was 33·6% (27·9-40·2) and 4-year TRM was 19·6% (15·1-25·3). 27 (56%) of 48 patients with TRM had infection as the named cause of death. Seven (15%) of 48 patients had fungal infections, 13 (27%) patients had bacterial infections (six gram-negative), and 11 (23%) had viral infections (three cytomegalovirus and two Epstein-Barr virus). Acute GVHD grade 2-4 occurred in 29 (12%) of 247 patients and grade 3-4 occurred in 12 (5%) patients. Chronic GVHD incidence was 84 (37%) of 228 patients (50 [22%] had extensive chronic GVHD). 49 (30%) of 162 patients had detectable end-of-induction MRD, which portended worse outcomes with event-free survival (HR 2·40 [95% CI 1·46-3·93]) and time-to-relapse (HR 2·41 [1·29-4·48]). INTERPRETATION: FMA reduced-intensity conditioned allogeneic HSCT in older patients with acute lymphoblastic leukaemia in first complete remission provided good disease control with moderate GVHD, resulting in better-than-expected event-free survival and overall survival in this high-risk population. Strategies to reduce infection-related TRM will further improve outcomes. FUNDING: Cancer Research UK.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Marks DI, Clifton-Hadley L, Copland M, et al. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. Lancet Haematol. 2022. PMID: 35358442. doi:10.1016/S2352-3026(22)00036-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。